CA
NZ
UK
AU
IND
US
● International medical revenue rose 17% to C$43.3 million.
● The trial enrolled 542 participants with early Alzheimer's disease.
● Management says the balance should fund operations into early 2027.
● The study compares 35 mg/kg and 50 mg/kg doses against placebo over 18 months.
● Management says the balance funds operations into the second half of 2028.
● A $100 million offering included a $40 million strategic investment by Eli Lilly.
● Second-quarter sales were $12.593 billion, up 13.0% reported and 4.8% comparable.
● Second-quarter net sales were $12,593 million, up 13.0% reported and 4.8% comparable.
Abbott Laboratories goes ex-dividend on October 15 for a quarterly dividend of USD 0.63 per share, payable on November 16, and the board has increased its dividend payout for 54 consecutive years, making it a Dividend Aristocrat. The 2026 quarterly dividend of USD 0.63 …
Main Drivers and Recent Developments
Please wait processing your request...